专业医美生物科技公司Evolus Inc.（纳斯达克：EOLS）近日发布2026年第一季度财务报告，继去年第四季度后再度实现调整后税息折旧及摊销前利润（EBITDA）转正，标志着公司盈利能力的持续改善。基于强劲的开年表现，管理层同时重申了对全年业绩的乐观预期。
财报数据显示，公司核心产品在竞争激烈的医美市场保持增长动能，运营效率提升计划成效显著。连续两个季度达成调整后EBITDA盈利目标，反映出公司商业化战略的有效执行与成本管控能力的强化。管理层在财报中强调，这一里程碑为后续创新产品管线推进提供了财务支撑。
尽管面临宏观经济不确定性，公司仍维持2026全年营收与利润指引不变，彰显其对业务韧性的信心。分析师指出，调整后EBITDA的持续改善可能为股价提供支撑，市场将关注下半年新市场拓展与产品组合优化进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.